Glaxo's rise in May was precipitated by two catalysts. First, the drugmaker's new managerial team, headed by CEO Emma Walmsley (who took over in March), has been indicating that they might be open to accelerating the company's …
One stock that might be an intriguing choice for investors right now is GlaxoSmithKline plc GSK. This is because this security in the Large Cap Pharmaceuticals space is seeing solid earnings estimate revision activity, and is in great …
Glaxosmithkline has a share of around 5% of the world's pharmaceutical market, aiming to tackle 3 of the 'priority' diseases identified by the World Health Organisation. The company employs around 96,500 people in over 100 …
I initiated a position in GSK recently. The stock is attractively priced, partly due to currency effects, and the weak pound will continue to be a tailwind for the business. The company returned to growth, but it needs to gain more momentum. …